
Index

A

- Abdominal TES
 - constipation and FI, 227–228
 - description, 227
 - mechanism, 228
 - surface electrodes, 227
- Acute urinary retention, 47
- Adverse events (AE), 72
- Adynamic Graciloplastyoy, 124
- Afferent innervation
 - animal models, 6
 - C-fibers, 6
 - electrophysiological studies, 5
 - interneurons/second order neurons, 5
 - micturition pathway, 5
 - neural circuits, 5, 6
 - pelvic, hypogastric and pudendal nerves, 5
- American Urological Association (AUA), 48
- Anal manometry, 121–122
- Animal electricity, 152
- Animal models
 - bladder capacity, 91
 - intermittent vs. continuous stimulation, 91
 - neurotransmitters, 90
 - tibial stimulation, 90–91
- Anorectal malformation, 225, 227, 229
- Antidepressant effect, 160
- Artificial bowel sphincter, 125

B

- Biofeedback therapy, 124
- Biowave, 190
- Bladder and bowel dysfunction (BBD)
 - DV, 207, 208
 - OAB, 207
- BlueWind, 191, 192
- Bowel Bladder Dysfunction (BBD), 233–235
- Brindley Finetech Stimulator, 54–56

C

- Cavernous nerve, 193
- Cerebral palsy (CP)

- rTMS, 172
- tDCS, 171, 172
- Cerebral vascular accident (CVA), 54–55
- ChlorPrep™, 36
- Chronic pain, 13–2020
- Chronic pelvic pain (CPP), *see also* Neuromodulation
 - AUA IC/PBS treatment
 - guidelines, 105
 - defined, 105
 - etiology, 105
 - IC/BPS, 106
 - pathophysiology, 105
 - pelvic floor, 105
 - pelvic structural configuration and complex neuroanatomy, 105
 - PTNS, 140
- Clean intermittent catheterization (CIC), 139
- Cleveland Clinic Florida Fecal Incontinence Score (CCF-FIS), 128
- Clinical application
 - depression, 158, 159
 - DTMS, 160, 161
 - rTMS, 158
 - tDCS, 161, 162
 - TMS, 157
- Complex regional pain syndrome (CRPS), 14
- Compound motor action potential (cMAP)
 - applications, 85
 - benefits, 77
 - electrical stimulus, 78
 - evaluation, 79
 - lead mapping, 83
 - lead placement guidance, 85
 - mechanism, 77
 - monitoring, 76–77
 - morphology, 77
 - operating room setup, 82
 - technology, 83
- Compound motor action potential (cMAP) guidance, 75
- Constipation
 - abdominal TES, 227–228
 - SNM, 225–226

D

- Deep brain stimulation (DBS), 14
 - clinical efficacy, 18
 - early preclinical studies, 17
 - early therapeutic effect, 17
 - functional imaging, 18
 - intracranial stimulation, 17
 - pain treatment modality, 17
 - preoperative planning, 17
 - sensory-discriminative components, 18
 - sensory thalamus stimulation, 17
- Deep transcranial magnetic stimulation (DTMS)
 - antidepressant effect, 160, 161
 - open-label studies, 160, 161
 - placebo effect, 161
 - RCT, 160

Defecating proctogram, 123

Defecating proctography, 123

Depression

- LDLPFC, 158
- MDD, 158
- rTMS, 158, 159
- TMS, 159

Detrusor areflexia, 7

Detrusor-external sphincter dyssynergia (DESD), 7

Detrusor sphincter dyssynergia (DSD), 208

Detrusor underactivity (DU), 54, 55, 57

Dietary modification, 123

Discrete neurologic lesions, 3

Diverting colostomy, 126

Dorsal genital nerve (DGN), 86, 193

Dynamic and adynamic gracilis flap, 124

Dynamic graciloplasty, 124, 126

Dysfunctional elimination syndrome (DES), 233

Dysfunctional voiding (DV), 207, 208, 213

- biofeedback therapy, 219
- diagnosis, 219

E

Efferent innervation

- bladder sympathetic nerves, 4
- detrusor contraction and resultant urinary flow, 4
- motor nerves, 5
- pelvic, hypogastric and pudendal nerves, 4
- pre- and postganglionic parasympathetic nerves, 4
- surgical injury/pharmacologic blockade, 5
- urethral smooth muscle relaxation, 5

Electrical pudendal nerve stimulation (EPNS), 101

Electrical stimulation (ES), 152

Electroencephalography (EEG), 156, 158, 162, 163, 167–170

Electrode, 81–82

Electroneurodiagnostics, 75, 76

Electroneurostimulation (ENS), 207, 209, 210, 219

Endoanal ultrasound, 122–123

Enuresis, 201, 205

Epilepsy, 168–170

- CSWSS, 167, 168
- rTMS

ECT, 169, 170

low- and high-frequency, 170

RE and EPC, 170

sham-controlled RCTs, 170

seizure frequency, 167

sham-controlled RCTs, 167

tDCS

cathodal, 168

and EEG testing, 168

RE, 169

Equipment setup, 81

Erectile dysfunction, 193

External programmable generator (EPG), 72

External urethral sphincter (EUS), 3

F

Failed back surgery syndrome (FBSS), 14

Fecal incontinence (FI), 102–103

abdominal TES, 227–228

accidental bowel leakage, 120

face to face/phone interviews, 119

anal manometry, 121–122

categories, 119

defecating proctography, 123

description, 119

diagnostics, 121

endoanal ultrasound, 122–123

intact rectal and anal sensations, 119

medical management

biofeedback therapy, 124

dietary modification, 123

MRI, 123

neurologic pathology, 120

neuromodulation, 126–128

overlapping sphincteroplasty, 124–125

patient history, 120

physical examination, 120–121

PNTML, 122

PTNS, 139, 140

rectal compliance, 120

sacral neuromodulation, 128

severity index, 121

SNM, 224–228

stool consistency, 120

surgical management

accidental bowel leakage, 120

artificial bowel sphincter, 125

diverting colostomy, 126

dynamic and adynamic gracilis flap, 124

injectables, 125

overlapping sphincteroplasty, 124–125

SECCA[®] procedure, 125–126

Fowler's syndrome, 50–53

G

Gate control theory, 13

H

H-coil deep TMS system, 160
 Hemilaminectomy, 56
 High-Definition tDCS (HD-tDCS), 165
 Hunner's lesions fulguration, 108–109
 Hydrodistension, 108–109
 Hyperalgesia, 106, 111

I

Idiopathic OAB
 diagnosis and treatment algorithm, 136, 137
 IUGA and ICS, 136
 OrBIT, 136
 OrBIT and SUmiT trials, 138
 person's quality of life (QoL), 136
 RCTs and systematic reviews, 136
 STEP study, 138
 SUmiT Trial, 136
 sustained symptom improvement, 138
 Idiopathic overactive bladder, 99, 101
 Implantable generator, 146, 149
 Implantable nerve stimulators, 190, 191, 193
 Implantable pulse generator (IPG), 185
 International Continence Society (ICS), 136
 International Urogynecological Association (IUGA), 136
 InterStim[®], 145, 146, 148
 Interstitial cystitis/bladder pain syndrome (ICBPS), *see also* Cyclosporine A (CyA)
 assessment, 106
 and CPP, 111–114
 heparin, 108
 Hunner's lesions fulguration, 108–109
 hydrodistension, 108–109
 hydroxyzine, 108
 intravesical lidocaine functions, 108
 intravesical therapies, 108
 lead placement, 113
 manual physical therapy techniques, 107
 multimodal pain management, 107
 oral medications, 107
 patient education and lifestyle modification, 106–107
 pentosan polysulfate, 108
 Intracortical inhibition (ICI), 163
 Intraoperative program recording sheet, 83
 Intrathecal (IT) drug delivery
 clonidine, alpha-2 adrenergic agonist, 20
 IPG, 144, 147, 148
 local anesthetics use, 20
 medical treatment patients, 19
 morphine use, 19
 on- and off-label agents, 20
 pain practitioners, 19
 trialed and additional agents, 19
 ziconotide, 19
 Ischiorectal approach, 96

J

Jackson fluoroscopy, 36

K

Kegel exercises, 124

L

Lead
 anchoring systems, 145
 complications, 147
 infection, 146, 148
 Medtronic InterStim[®] lead and neurostimulator, 145
 percutaneous SNS, 145
 PNE, 146
 tined, 144, 145
 Lead placement, 94
 Lead tunneling trocar, 38, 39
 Lennox–Gastaut syndrome (LGS), 168
 Lower urinary tract dysfunction (LUTD), 31, 201
 Lower urinary tract (LUT), 209, 210
 afferent innervation, 5–7
 continence, 3
 discrete neurologic lesions, 3
 efferent innervation, 4, 5
 EUS relaxation and bladder contraction, 3
 local, spinal and brain circuits, 3
 operation modes, 3
 peripheral nerves, 3
 Lower urinary tract symptoms (LUTS), 47, 143
 BBD, 207
 SNM, (*see* Sacral neuromodulation (SNM))
 Lumbar sympathetic nerves, 3

M

Maastricht-Hannover nomogram, 57
 Magnetic resonance imaging (MRI), 123
 Major depressive disorder (MDD), 158, 160
 Medtronic[®], 71
 Medtronic[™], 57
 Medtronic Verify[™] system, 72
 Motor cortex stimulation (MCS), 14
 beneficial stimulation parameters, 19
 case reports and series evaluation, 18
 central deafferentation pain syndromes, 18
 neuropathic pain forms, 18
 positron emission tomography studies, 19
 trigeminal neuropathic pain treatment, 18
 Multiple sclerosis (MS), 7, 55, 138, 139
 Myelomeningocele, 55–56

N

National Overactive Bladder Evaluation (NOBLE) study, 26
 Neuroanatomy, 209
 Neurogenic bladder, 138
 Neurogenic detrusor overactivity (NDO), 7
 Neurogenic dysfunction
 autonomic hyperreflexia, 8
 basal ganglia and thalamus, 7
 coordinated sphincter function, 7

- Neurogenic dysfunction (*cont.*)
 DESD, 7
 detrusor areflexia, 7
 detrusor underactivity (DU) treatment, 8
 electrical stimulation, low frequencies, 1
 MS, 7
 NDO, 7
 neuromodulation, 8
 PD, 7
 SCI, 7
- Neuromodulation, 75
 caudal epidural SNS, 114
 chemical modulation, drug delivery, 14
 CPP treatment, 113
 FDA treatment, pelvic organ disorders, 8
 feline animal model, 9
 gate control theory, 13
 implantable devices, 14
 implantable stimulator devices, 13
 inhibitory neurotransmitter GABAA, 9
 intact supraspinal pathways, 9
 motor cortex stimulation, 14
 multicenter randomized controlled trials, 114
 neurosurgical treatment, pain, 13–14
 normal nervous system activity, 13
 pelvic, 8
 personal, social and economic burden, 13
 positive pudendal response, 114
 pudendal neuromodulation, 9
 refractory IC underwent placement, 114
 SNM and PTNS, 8
 somatic afferent nerves, 8
 STAR technique, 114
 TNS and PNS, 9
- Neuropathic pain (NP), 163–165
 EEG, 163
 EMCS, 162
 PFC, 163
 rTMS, 162
 M1 stimulation, 163
 treatment efficacy, 164
 tDCS, 164
 HD-tDCS, 165
 M1 stimulation, 164
 SCI, 165
 treatment efficacy, 165
- Nocturia, 201, 204
 Nocturnal enuresis (NE), 213
 Non-invasive brain stimulation (NIBS), 152
 tDCS, 152
 TES, 152
 TMS, (*see* Transcranial magnetic stimulation (TMS))
- Non-obstructive urinary retention, 138
 behavioral causes, 57
 causes, 48
 closed-loop feedback, 57
 DU, 57
 Fowler's syndrome, 50
 idiopathic causes, 48–53
 literature, 52
 LUTS, 47
 neurogenic causes, 53
 sacral neuromodulation, 54
 urodynamic tracing, 49
- Normal bladder filling and emptying, 208
- O**
 OAB Innovative Therapy trial (OrBIT), 136
 Occipital nerve stimulation (ONS), 16
 Overactive bladder (OAB), 202–204, 207, 208
 anticholinergics, 211
 clinical factors, 28
 definitions and terminology, 25–26
 diagnosis, 219
 epidemiology, 26
 guidelines, 29
 literature reviews, 31
 LUTD, 31, 32
 LUTS, 212
 management, 27
 MRI and pregnancy, 28
 neuromodulation, 32
 origin, 26
 patient counseling, 28–29
 patient evaluation, 29
 patient selection, 28
 PTENS, 212
 randomized trials, 30–31
 sham treatment, 212
 SNM, 27
 symptom, 26
 treatments, 27
 urotherapy, 211, 212
- P**
 Parasacral electrical stimulation, *see* Pediatric PTENS
 Parkinson's disease, 7, 33, 139
 Pediatric defecatory disorders
 constipation, 223
 conventional treatment, 223
 invasive treatment options, 224
 population-based studies, 223
 SNM, (*see* Sacral neuromodulation (SNM))
- Pediatric PTENS
 constipation, 217, 218
 DV, 216
 dysfunctional voiding, 213
 electrode placement, 210, 211
 nocturnal enuresis, 216
 OAB, 214, 215
 overactive bladder, 211–213
 recurrence rate, 217
 side effects, 217
- Pediatrics, 167
 epilepsy, (*see* Epilepsy)
 PTNS, 202
 safety, 166
 tDCS, 166
 TMS, 166
- Pediatric sacral neuromodulation, 234, 235

- Pelvic floor dysfunction, 111
 Pelvic neuromodulation, 75, 78, 83
 Pelvic pain, 102
 Pelvic parasymphathetic nerves, 3
 Percutaneous nerve evaluation (PNE), 143, 146
 Percutaneous PTNS, 202–204
 Percutaneous tibial nerve stimulation (PTNS), 136–138
 CPP, 140
 electrical stimulation therapy, 131
 FDA, OAB treatment, 131
 FI, 139, 140
 idiopathic OAB, (*see* Idiopathic OAB)
 lower urinary tract neuromodulation, 131
 MS, 138, 139
 needle placement and setup, 134, 135
 neurogenic bladder, 138
 non-neurogenic bladder overactivity, 131
 nonobstructive urinary retention, 138
 patient evaluation, 132–134
 PD, stroke and spinal cord injury, 139
 posterior tibial nerve, 134
 sacral plexus, 131, 132
 spinal interneurons, 131, 133
 treatment protocols, 136
 troubleshooting, 135
 Peripheral nerve evaluation (PNE), 185
 advantages/disadvantages, 72
 AEs, 72
 contraindication, 64
 fluoroscopy, 66
 patient selection, 63–64
 stimulation kit, 64
 sub-acute trial phase, 68
 Peripheral nerve stimulation (PNS)
 headaches and facial pain, 16
 median nerve injury, 16
 ONS, 16
 pain signals suppression, 16
 percutaneous surgical technique, 16
 peripheral nerve etiology, 16
 sphenopalatine ganglion, 16
 Peripheral tibial nerve stimulation (PTNS)
 biowave, 190
 external wireless power sources, 190, 191
 OrBIT, 190
 SUMiT, 190
 Polarization, 154
 Pontine micturition center (PMC) gating circuits, 5, 132
 Posterior tibial nerve stimulation (PTNS)
 conventional treatments, 205
 history, 201–202
 neuromodulation, 201
 non-neurogenic LUTD, 201
 obstipation and behavioral problems, 201
 pediatric urologists, 201
 percutaneous, 202–204
 transcutaneous, 203–205
 treatment sessions, 205
 Prefrontal cortex (PFC), 163
 Pudendal nerve (PN), *see also* Animal models
 anatomy, 90
 chronic non-obstructive UR, 102
 complications, 97, 98, 100
 fecal incontinence (FI), 102–103
 in humans, 91
 idiopathic overactive bladder, 99, 101
 motor and sensory innervation, 89
 neurogenic OAB, 101–102
 neuromodulation, 89
 patient selection and perioperative counseling, 91–92
 pelvic pain, 102
 surgical techniques
 access to, 93
 ischial spine landmark, 93
 ischial tuberosities, 92, 93
 laparoscopic approach, 96
 lead placement, 94
 positioning, EMG needle placement
 and draping, 92–93
 posterior/ischioirectal approach, 96
 STAR method, 96, 99, 102
 temporary percutaneous extension, 95, 99
 tined lead placement, 94–98
 vesicoinhibitory influence, 89
 Pudendal nerve stimulation (PNS), 9, 113, 114
 Pudendal nerve terminal motor latency
 (PNTML) testing, 122
 Pudendal neuromodulation, 77, 86
 Pudendal somatic nerves, 3
 Primary monosymptomatic nocturnal enuresis
 (PMNE), 213
 Pulsed radiofrequency (PRF) stimulation, 91
- Q**
 Quality of life, 26, 27, 29
- R**
 Rasmussen's encephalitis (RE), 168
 Rechargeable nerve stimulators, 187, 190, 191
 Rectoanal inhibitory reflex (RAIR), 121
 Repetitive TMS (rTMS), 159
 Repetitive transcranial magnetic stimulation
 (rTMS), 163–165
 categories, 158
 clinical applications, 158
 CP, 172, 173
 depression, 158, 159
 DTMS, 161
 epilepsy, 169, 170
 NIBS
 M1 stimulation, 163
 treatment efficacy, 164, 165
 safety, 157
- S**
 Sacral nerve
 battery technology, 187
 external power sources, 187
 IPG pain reduction, 185

- Sacral nerve (*cont.*)
 lead placement, 188
 MRI, 186
 nerve targets, 189
 programming parameters, 187
 staged procedure, 188
- Sacral nerve stimulation (SNS), 109–110
 complications, 128–129
 intradetrusor botulinum toxin injection, 109
 mean battery life, 110
 refractory IC/BPS symptoms, 109
 retreatment, 109
- Sacral neuromodulation (SNM), 144–146
 advanced evaluation, 35–39
 basic evaluation, 34–35
 complications, 226
 device-related, 144, 145
 patient-related, 146
 response-related, 146
 constipation and FI, 225–226
 cost-effectiveness, 41
 dexmedetomidine, 36
 electrical stimulation, 144
 first-line treatment, 233
 functional response evaluation, 128
 impedance testing, 147
 InterStim® system, 128
 intravesical pressures, 234
 intubation purposes, 128
 IPG-2, 147
 mechanisms, 226–227
 needle placement, 35
 neurogenic bladder dysfunction, 234
 neurogenic/non-neurogenic, 234
 neuromodulation-based treatments, 224
 OAB, 30
 pediatric bowel and bladder dysfunction, 224–225
 pediatric, 234, 235
 permanent implantable pulse generator, 128
 permanent implantation, 224
 PNE, 143
 stimulation, 148
 test stimulation, 37
 test technique, 33
 tunneling device, 38
 two-stage tined lead placement, 144
- Sacral peripheral nerve stimulation, 78
- Sacrospinous ligament (SSL), 96
- Safety guidelines, 156, 157
 tDCS, 156
 TMS
 burns, 157
 cognition, 157
 headache, 157
 hearing, 156
 local pain, 157
 neuropsychological changes, 157
 seizure, 156
- SECCA® procedure, 125–126
- Sierra®, 80
- Single-pulse TMS (spTMS), 157, 158
- Spinal cord injury (SCI), 7, 32, 53, 165
- Spinal cord stimulation (SCS)
 anti-anginal and anti-ischemic effects, 15
 clinical and observational evidence, 16
 conventional stimulation parameters, 15
 DRG stimulation, 15
 epidural electrode placement, 14
 FBSS and CRPS, 14
 long-term observations, 14
 neuropathic axial pain, 14
 “pain-like behaviors”, 16
 peripheral vascular disease and angina pectoris, 15
- S3 sacral nerve, 111–113
- StimGuard, 187, 191, 192
- StimWave, 187, 189
- Subsensory programming, 86
- T**
- Tegaderm™, 64
- Test stimulation, 63, 64, 66, 67, 71, 72
- Tined lead, 144–147
- Tined lead electrode (TLE), 72
- Tined lead placement, 94–98
- Transcranial direct current stimulation (tDCS)
 anodal after-effects, 154
 antidepressants, 162
 cathodal stimulation, 155
 CP, 171, 172
 CSF, 155
 depression, 161, 162
 drug effects, 169
 epilepsy, 167, 168
 fMRI and EEG, 154
 HD-tDCS, 165
 LDLPFC and RDLPFC, 161
 neurorehabilitation, 155
 NP, 164
 pediatric patients, 166, 167
 relapse, 162
 safety, 155, 156
- Transcranial electrical stimulation (TES), 154, 155
- Transcranial magnetic stimulation (TMS)
 capacitor, 152
 coils, 153
 depression, 159
 electromagnetic field, 154
 epilepsy, 169, 170
 induced electric field, 153
 pediatric patients, 166, 167
 rTMS, 158
 safety, 155–157
 spTMS, 157
- Transcutaneous PTNS, 203–205
- Two-stage tined lead technique, 144
- U**
- Ultrasound guidance, 66
- Urge incontinence, 27, 39
- Urinary frequency, 32, 39, 53, 55, 56

Urinary incontinence, 31, 32, 208, 211, 212
Urinary retention (UR), 63, 102
Urinary urgency, 211, 213
Urinary urgency incontinence (UUI), 63
Urine storage reflexes, 6
Urodynamic studies (UDS), 234

V

Verify™, 39
Visual analog scale (VAS), 112
Voiding dysfunction
 careful consideration, patient selection, 236

 congenital neurogenic patients, 236
 DES and BBD, 233
 long-term success and complication rates, 236
 pediatric population, 233
 pharmacologic agents, urinary symptoms, 233
 radiation exposure, 235
 second stage procedure, 235
Voiding reflexes, 6

X

Xiao procedure, 56